Torsades de pointes

  • Sami Viskin

Opinion statement

The treatment of torsades de pointes is very effective but also very specific. Prompt recognition of torsades de pointes is imperative, and the clue to its recognition is increased awareness. The QT interval in the long QT syndrome (LQTS) is not only prolonged but also odd looking. This abnormal QT morphology, which has been well described for the congenital LQTS, is also observable in the acquired LQTS. Moreover, the onset of ventricular extrasystoles and the appearance of bizarre QT changes (with gian U waves) in the sinus complex that follows each postextrasystolic pause are signs of "impending torsades." Emergency treatment includes 1) withdrawal of any precipitating agents; 2) intravenous administration of magnesium sulfate, potassium supplements, and lidocaine; and 3) adequate sedation. For drug-refractory torsades de pointes, transvenous ventricular pacing at rapid rates will shorten the QT interval, eliminate the pauses that precipitate torsades, and prevent further bursts of arrhythmias. Acceleration of the basic heart rate with isoproterenol is also effective in preventing immediate recurrence. Isoproterenol should only be used, however, when 1) torsades de pointes is due to an acquired LQTS; 2) the underlying rhythm is slow, and torsades is clearly "pause dependent"; and 3) transvenous pacing cannot be immediately implemented.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Roden D: Recent advances in the long QT syndrome. Cardiac Electrophysiol Rev 1997, 1:262–263.CrossRefGoogle Scholar
  2. 2.
    Roden D, Lazzara R, Rosen M, et al.: Multiple mechanisms in the long QT syndrome. Current knowledge, gaps, and future directions. Circulation 1996, 94:1996–2012.PubMedGoogle Scholar
  3. 3.
    Tan HL, Hou CJ, Lauer MR, Sung RJ: Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 1995, 122:701–714. A very clear explanation of the normal (and abnormal) physiology at the level of cardiac membrane ion channels.PubMedGoogle Scholar
  4. 4.
    Jackman WM, Friday KJ, Anderson JL, et al.: The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988, 31:115–172. Although a little bit outdated, this beautiful review was the first to explain the similarities between the congenital and the acquired forms of the diseasePubMedCrossRefGoogle Scholar
  5. 5.
    Priori SG, Napolitano C, Paganini V, et al.: Molecular biology of the long QT syndrome: impact on management. Pacing Clin Electrophysiol 1997, 20:II2052-II2057.CrossRefGoogle Scholar
  6. 6.
    Viskin S: The long QT syndromes and torsades de pointes. Lancet 1999, in press Google Scholar
  7. 7.
    Yang T, Roden D: Extracellular potassium modulation of drug block of IKr: implications for torsades de pointes and reverse use-dependence. Circulation 1996, 93:407–411.PubMedGoogle Scholar
  8. 8.
    Antzelevitch C, Sun Z, Zhang Z, Yan G: Cellular and ionic mechanisms underlying erythromycin-induce long QT intervals and torsades de pointes. J Am Coll Cardiol 1996, 28:1836–1848.PubMedCrossRefGoogle Scholar
  9. 9.
    Vorperian V, Zhou Z, Mohammad S, et al.: Torsades de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996, 28:1556–1561.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang Z, Boutjdir M, El-Sherif N: Ketanserin inhibits depolarization-activated outward potassium current in rat ventricular myocytes. Circ Res 1994, 75:711–721.PubMedGoogle Scholar
  11. 11.
    Drolet B, Khalifa M, Daleau P, et al.: Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998, 97:204–210.PubMedGoogle Scholar
  12. 12.
    Zareba W, Moss AJ, Rosero S, et al.: Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997, 80:1168–1173.PubMedCrossRefGoogle Scholar
  13. 13.
    Pinto YM, Van Gelder IC, Heeringa M, et al.: QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter]. Lancet 1999, 353:980.PubMedCrossRefGoogle Scholar
  14. 14.
    Kay GN, Plumb VJ, Arciniegas JG, et al.: Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983, 2:806–817. The first description of the mode of onset of torsades de pointes and the "long-short sequence" in the acquired long QT syndrome.PubMedCrossRefGoogle Scholar
  15. 15.
    Viskin S, Alla S, Barron H, et al.: Mode of onset of torsades de pointes in congenital long QT syndrome. J Am Coll Cardiol 1996, 28:1262–1268. Contrary to previously published reports, this report suggests that the majority of episodes of torsades de pointes in the congenital long QT syndrome have a mechanism similar to the one described in the acquired form (ie, the long-short sequence).PubMedCrossRefGoogle Scholar
  16. 16.
    Viskin S, Fish R, Zeltser D, et al.: Pause-dependent vs. non pause-dependent initiation of torsades de pointes in the congenital long QT syndrome [abstract]. Pacing Clin Electrophysiol 1998, 21 (Part II):II851.Google Scholar
  17. 17.
    Locati EH, Maison-Blanche P, Dejode P, et al.: Spontaneous sequences of onset of torsades de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J Am Coll Cardiol 1995, 25:1564–1575. A detailed analysis of the "long-short" sequence in drug-induced torsades de pointesPubMedCrossRefGoogle Scholar
  18. 18.
    Antzelevitch C, Sicouri S: Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsades de pointes. J Am Coll Cardiol 1994, 23:259–277. This article describes how different areas in the heart have different propensities to develop delayed repolarization and early afterdepolarizations, explaining the mechanism of the pathologic U waves observed in the long QT syndrome.PubMedCrossRefGoogle Scholar
  19. 19.
    Davidenko JM, Cohen L, Goodrow R, Antzelevitch C: Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium. Circulation 1989, 79:674–686.PubMedGoogle Scholar
  20. 20.
    Kurita T, Ohe T, Shimizu W, et al.: Early afterdepolarization in a patient with complete atrioventricular block and torsades de pointes. Pacing Clin Electrophysiol 1993, 16(1 Pt 1):33–38.PubMedCrossRefGoogle Scholar
  21. 21.
    El-Sherif N, Bekheit SS, Henkin R: Quinidine-induced long QTU interval and torsades de pointes: role of bradycardia-dependent early afterdepolarizations. J Am Coll Cardiol 1989, 14:252–257.PubMedCrossRefGoogle Scholar
  22. 22.
    El-Sherif N, Chinushi M, Caref E, Restivo M: Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsades de pointes tachyarrhythmias in the long QT syndrome. Detailed analysis of ventricular tridimensional activation patterns. Circulation 1997, 96:4392–4399. A very clear model explaining the genesis of the "twisting" morphology of torsades de pointes.PubMedGoogle Scholar
  23. 23.
    Roden D: Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998, 21:1029–1034.PubMedCrossRefGoogle Scholar
  24. 24.
    Schwartz PJ, Periti M, Malliani A: The long Q-T syndrome. Am Heart J 1975, 89:378–390. The first comprehensive review of the congenital long QT syndrome.PubMedCrossRefGoogle Scholar
  25. 25.
    Tzivoni D, Keren A, Cohen A, Stern S: Magnesium therapy for torsades de pointes. Am J Cardiol 1984, 53:528. Although it is not at all clear why the authors decided to try magnesium therapy, this report is the first to show the lifesaving effects of this therapy.PubMedCrossRefGoogle Scholar
  26. 26.
    Tzivoni D, Banai S, Schuger C, et al.: Treatment of torsades de pointes with magnesium sulfate. Circulation 1988, 77:392–397.PubMedGoogle Scholar
  27. 27.
    Bailiei D, Inoue H, Kaseda S, et al.: Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation 1988, 77:1395–1402.Google Scholar
  28. 28.
    Nattel S, Quantz M: Pharmacological responses of quinidine induced early afterdepolarizations in canine cardiac Purkinje fibers: insights into underlying ionic mechanisms. Cardiovasc Res 1988, 22:808–817.PubMedCrossRefGoogle Scholar
  29. 29.
    Verduyn S, Vos M, Zande J, et al.: Role of interventricular dispersion of repolarization in acquired torsades de pointes arrhythmias: reversal by magnesium. Cardiovasc Res 1997, 34:453–463.PubMedCrossRefGoogle Scholar
  30. 30.
    Sclarovsky S, Strasberg B, Lewin R, Agmon J: Polymorphous ventricular tachycardia: clinical features and treatment. Am J Cardiol 1979, 44:339–345.CrossRefGoogle Scholar
  31. 31.
    Keren A, Tzivon D, Gavish D, et al.: Etiology, warning signs and therapy of torsades de pointes. A study of 10 patients. Circulation 1981, 64:1167–1174.PubMedGoogle Scholar
  32. 32.
    Choy A, Lang C, Chomsky D, et al.: Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997, 97:2149–2154.Google Scholar
  33. 33.
    Wolfe CL, Nibbley C, Bhandari A, et al.: Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991, 84:1543–1551.PubMedGoogle Scholar
  34. 34.
    Leenhardt A, Lucet V, Denjoy I, et al.: Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995, 91:1512–1519.PubMedGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Sami Viskin
    • 1
  1. 1.Department of CardiologySourasky-Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv UniversityTel AvivIsrael

Personalised recommendations